7210 Wareham Drive, Tampa, FL 33647
Sept. 23, 2025 Pfizer has agreed to pay up to $7.3 billion for weight-loss drug developer Metsera in a deal that provides a re-entry for the company into the market for obesity drugs. Pfizer on Monday said it will pay an initial $47.50 a share, or about $4.9 billion, for Metsera, a nearly 43% premium […]
Pfizer to Buy Weight-Loss Drug Developer Metsera Read More »
May 6, 2025 WW management reported first quarter 2025 results today. “We are making progress on our strategic priorities with continued momentum in our Clinical business, while laying the foundation for long-term, sustainable growth,” said Tara Comonte, President and CEO. “As the weight management landscape evolves, we believe our unique combination of science-backed behavioral support,
Weight Watchers Reports Q1 Results Read More »
April 30, 2025 Herbalife today reported its first quarter 2025 results. The company sells a significant amount of weight management products (meal replacements), and is one the the leading MLM companies selling weight loss products. At $254.4 million, North American sales represented 20.8% of total Herbalife revenues for the quarter. The company had worldwide weight
Herbalife Reports Q1 2025 Results Read More »
April 29, 2025 WW announced a pharmacy integration with Eli Lilly and Company’s LillyDirect® pharmacy provider, Gifthealth. The integration will streamline access to Lilly’s FDA-approved Zepbound® (tirzepatide) single-dose vials for WeightWatchers Clinic members with an on-label prescription from their clinician. As part of WeightWatchers’ holistic approach to weight management, the integration will streamline access to
Weight Watchers Streamlines Member Access to Zepbound® Vials Read More »
April 28, 2025 According to CEO Dan Chard: “This year, we are focused on revitalizing our coach and customer base by supporting them with enhanced tools, data, and new products. Our business focus remains on reestablishing sustainable long-term growth while improving profitability.” First quarter 2025 revenue decreased 33.8% to $115.7 million from $174.7 million for the
Medifast Reports First Quarter Results – Slide Continues Read More »
April 24, 2025 The U.S. Census of Service Industries is performed every 5 years, with the last government survey performed in 2022. Commercial weight loss companies (“diet & reducing centers”) are classified under NAICS code 812191 (other personal services). Establishment and firms data for this industry have just been released (see census.gov). This information is
2022 Census Data Published: Commercial Weight Loss Industry Statistics Read More »
April 3, 2025 Premca Capital, an investment fund, has nominated three directors for election to WW International’s board, according to the people familiar with the matter. WW has a market capitalization of about $40 million, following a sharp decline in its shares in recent years. Its stock is down nearly 70% in the past year, due
Weight Watchers Investor Seeks Board Seats Read More »
March 13, 2025 Marketdata, the parent company of DietBusinessWatch.com, has updated its report on the Commercial & Retail Weight Loss Market. Several things have become apparent as we do the research Marketdata analysts see a possible opportunity this year for the commercial (non-medical) weight loss firms to recover some ground. Here’s how we think 2025
Recession Is Coming – But Commercial Diet Companies Could Benefit Read More »
April 13, 2024 Marketdata LLC (parent company of DietBusinessWatch) has just released new research, a report entitled: “The Telehealth Weight Loss Market”. The market for weight loss programs delivered via telehealth / telemedicine companies is worth $6.9 billion, and growing. Telehealth soared during the pandemic in 2020 as consumers stayed home and communicated with their
Telehealth Weight Loss Market Worth $6.9 Billion And Growing Read More »
January 4, 2024 The history of weight loss drugs in the U.S. is filled with meds that were taken off the market due to nasty side effects, going back to the phen/fen crisis of 1997. Many more followed (Belviq, Qsymia, Taranabant, Acomplia) . These side effects did not emerge until years after entering the market
Semaglutide Boom – The Beginning of a Decline? New FDA Report Read More »